冠心病患者抗血栓治疗疗效与安全性的性别差异:系统综述与荟萃分析
该系统综述与荟萃分析纳入33项随机对照试验、共274 433例冠心病患者(女性72 601例,中位比例25%),评估强化与较弱抗血栓策略的性别差异。结果显示两性在全因死亡、心肌梗死和主要出血方面均无显著性别交互作用,强化治疗在两性中均与心肌梗死风险降低约15%相关,主要出血风险增加约40%,疗效与安全性一致。
要点
- 共纳入33项随机对照试验、274 433例患者,女性72 601例(中位比例25%)。
- 强化与较弱抗血栓治疗的全因死亡风险两性相当,无性别交互作用(交互HR 1.06,95%CI 0.94~1.19)。
- 强化抗血栓治疗在两性中均与心肌梗死风险降低约15%相关,主要出血风险增加约40%,性别间无显著差异。
核心结论
- 在已确诊冠心病的患者中,抗血栓治疗在女性和男性中提供了疗效与安全性一致的结果。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid Medline和Embase数据库自建库至2025年4月。
- 纳入报告性别分层结局(缺血事件和主要出血事件)并比较任何试验性抗血栓策略与对照策略的随机对照试验。
- 共纳入33项试验,入组274 433例参与者,其中女性72 601例(中位比例25%),患者入组时间为1999年至2025年。
- 采用试验内框架评估抗血栓治疗效应的性别相关异质性,性别特异性风险估计以风险比及95%置信区间报告,试验水平风险比比值采用逆方差模型合并。
主要发现
- 22项试验共187 580例患者中发生6018例死亡(强化抗血栓治疗患者3064例死亡,较弱治疗患者2954例死亡),强化与较弱抗血栓治疗的全因死亡相对风险在女性和男性中相当,无性别交互作用(交互HR 1.06,95%CI 0.94~1.19;交互P=0.33;I²=0.00%;异质性P=0.76)。
- 172 504例患者中发生7558例心肌梗死,强化抗血栓治疗在男性和女性中均与心肌梗死风险降低约15%相关(交互HR 1.05,95%CI 0.95~1.17;交互P=0.36;I²=14.05%;异质性P=0.28)。
- 共发生4003例主要出血事件(强化治疗患者2384例,较弱治疗患者1619例),强化与较弱抗血栓治疗相比主要出血风险增加约40%,与性别无关(交互HR 0.99,95%CI 0.86~1.15;交互P=0.93;I²=33.56%;异质性P=0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate sex related differences in the treatment effect of antithrombotic therapy in patients with established coronary artery disease. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Ovid Medline and Embase databases from inception to April 2025. INCLUSION CRITERIA: Included studies were randomised controlled trials reporting sex stratified outcomes, including ischaemic and major bleeding events, and comparing any experimental versus control antithrombotic strategy in coronary artery disease. DATA EXTRACTION AND SYNTHESIS: Two reviewers extracted data and assessed the risk of bias. To avoid ecological bias, a within trial framework was developed to evaluate sex related heterogeneity in the treatment effect of antithrombotic therapies. Sex specific risk estimates were reported as hazard ratios with 95% confidence intervals, whereas trial level ratios of hazard ratios were pooled with an inverse variance model. RESULTS: A total of 33 trials enrolling 274 433 participants, of which 72 601 (median proportion 25%) were women, were included. Patients were enrolled between 1999 and 2025. A total of 6018 deaths occurred in 187 580 patients across 22 trials (3064 deaths in patients using more intensive antithrombotic therapies and 2954 in those using less intensive therapies). The relative risk of all cause death was comparable for more intensive versus less intensive antithrombotic therapies in both women and men, without sex based interaction (interaction hazard ratio 1.06, 95% confidence interval 0.94 to 1.19; P for interaction=0.33; I2=0.00%; P for heterogeneity=0.76). 7558 myocardial infarctions occurred among 172 504 patients. More intensive antithrombotic therapies were associated with a reduced risk of myocardial infarction by ~15% in both men and women (interaction hazard ratio 1.05, 0.95 to 1.17; P for interaction=0.36; I2=14.05%; P for heterogeneity=0.28). Conversely, major bleeding was significantly increased by ~40% for more intensive versus less intensive antithrombotic therapies irrespective of sex (interaction hazard ratio 0.99, 0.86 to 1.15; P for interaction=0.93; I2=33.56%; P for heterogeneity=0.05). Overall, 4003 major bleeding events occurred (2384 in patients using more intensive therapies and 1619 in those using less intensive therapies). CONCLUSIONS: Antithrombotic therapies in patients with established coronary artery disease provided consistent efficacy and safety outcomes in women and men. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024560908.
引用
- Piccolo R, Laino A, Vitale AP, et al. Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis. BMJ. 2025. PMID: 40730387. doi:10.1136/bmj-2024-082974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。